Sanofi gets positive results for eczema treatment – this time in young children
A new phase III study of Sanofi's Dupixent in very young children with moderate to severe atopic dermatitis has generated positive results.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Last year, Sanofi received authorization to market Dupixent as a treatment for childhood eczema to patients aged 6 and 11. Now, it seems that the company is setting its sights on even younger children.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
